Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
REGENXBIO Inc. (RGNX)
USD12.75
-1.20 (-8.60%)
US NASDAQ Healthcare Biotechnology
Address
9804 Medical Center Drive 20850
Rockville, MD, US
Rockville, MD, US
CEO
Curran Simpson
Website
regenxbio.com
IPO
2015-09-17
CIK 1590877 ISIN US75901B1070
Description
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD12.75
-1.20 (-8.60%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
1.03
Float Shares
43.00M
Free Float %
83.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -37.80% | -41.25% | -32.85% | -21.84% | -45.74% | -56.63% | -25.03% | -71.23% | -82.72% | -48.98% | -79.49% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (20 ratings, all time)
Buy
Price Targets & DCF
Current price
12.75
Low
12.00
-5.9%
Consensus
25.75
+102.0%
Median
23.50
+84.3%
High
45.00
+252.9%
Ratings Trend (MoM)
91% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 6 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 2 |
23.50
+84.3%
|
| Last Year | 10 |
27.20
+113.3%
|
| All Time | 20 |
29.60
+132.2%
|
Quality scores
Altman Z-Score
-5.85
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+104.5% ★ Q1'26: -92.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+18.1% Q1'26: -1,533.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-106.3% Q1'26: -1,211.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-94.6% Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-121.0% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+4.2% Q1'26: +1.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.79× Q1'26: -0.21× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 7 EPS Ana. |
Dec 2027 6 Rev. Ana. 5 EPS Ana. |
Dec 2028 5 Rev. Ana. 5 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
7.59M
est: 4.82M (+57.6%)
|
4.59M
est: 5.56M (-17.5%)
|
10.39M
est: 8.94M (+16.3%)
|
218.51M
est: 207.06M (+5.5%)
|
35.23M
est: 53.96M (-34.7%)
|
154.57M
est: 159.42M (-3.0%)
|
470.35M
est: 492.16M (-4.4%)
|
112.72M
est: 120.42M (-6.4%)
|
90.24M
est: 89.04M (+1.3%)
|
83.33M
est: 86.91M (-4.1%)
|
170.44M
est: 184.60M (-7.7%)
|
252.45M
163.41M – 378.37M
+36.8% YoY
|
297.18M
189.91M – 509.80M
+17.7% YoY
|
492.90M
477.66M – 508.14M
+65.9% YoY
|
739.77M
431.17M – 1.19B
+50.1% YoY
|
995.91M
580.46M – 1.60B
+34.6% YoY
|
| EBITDA |
-22.71M
est: -3.15M (-622.0%)
|
-64.80M
est: -3.63M (-1,684.1%)
|
-73.20M
est: -5.84M (-1,153.9%)
|
92.08M
est: 134.44M (-31.5%)
|
-90.34M
est: -62.33M (-44.9%)
|
-96.83M
est: -104.13M (+7.0%)
|
169.54M
est: -321.48M (+152.7%)
|
-244.24M
est: -135.79M (-79.9%)
|
-239.46M
est: -62.22M (-284.9%)
|
-198.23M
est: -60.72M (-226.4%)
|
-145.58M
est: -128.99M (-12.9%)
|
-176.40M
-264.38M – -114.18M
-36.8% YoY
|
-207.65M
-356.22M – -132.69M
-17.7% YoY
|
-344.41M
-355.06M – -333.76M
-65.9% YoY
|
-516.91M
-829.30M – -301.28M
-50.1% YoY
|
-695.88M
-1.12B – -405.59M
-34.6% YoY
|
| EBIT |
-22.79M
est: -3.22M (-608.3%)
|
-65.34M
est: -3.71M (-1,658.9%)
|
-75.89M
est: -5.97M (-1,170.8%)
|
88.10M
est: 104.74M (-15.9%)
|
-97.49M
est: -139.24M (+30.0%)
|
-105.24M
est: -106.52M (+1.2%)
|
159.98M
est: -328.84M (+148.7%)
|
-257.15M
est: -151.14M (-70.1%)
|
-256.78M
est: -64.21M (-299.9%)
|
-214.44M
est: -62.67M (-242.2%)
|
-161.20M
est: -133.12M (-21.1%)
|
-182.05M
-272.85M – -117.84M
-36.8% YoY
|
-214.31M
-367.63M – -136.95M
-17.7% YoY
|
-355.45M
-366.44M – -344.46M
-65.9% YoY
|
-533.47M
-855.87M – -310.93M
-50.1% YoY
|
-718.17M
-1.15B – -418.58M
-34.6% YoY
|
| Net Income |
-22.81M
est: -93.08M (+75.5%)
|
-62.97M
est: -115.97M (+45.7%)
|
-73.17M
est: -135.98M (+46.2%)
|
99.94M
est: 120.19M (-16.9%)
|
-94.73M
est: -67.61M (-40.1%)
|
-111.25M
est: -141.24M (+21.2%)
|
127.84M
est: 192.69M (-33.7%)
|
-280.32M
est: -274.16M (-2.2%)
|
-263.49M
est: -241.08M (-9.3%)
|
-227.10M
est: -243.00M (+6.5%)
|
-193.88M
est: -193.88M (+0.0%)
|
-160.16M
-187.54M – -27.73M
+17.4% YoY
|
-152.94M
-399.26M – 49.60M
+4.5% YoY
|
-101.57M
-129.62M – -18.23M
+33.6% YoY
|
118.62M
54.29M – 211.81M
+216.8% YoY
|
324.91M
148.71M – 580.17M
+173.9% YoY
|
| SGA |
11.91M
est: 3.12M (+281.9%)
|
23.59M
est: 3.60M (+555.1%)
|
27.23M
est: 5.79M (+370.4%)
|
36.85M
est: 51.78M (-28.8%)
|
51.82M
est: 48.57M (+6.7%)
|
63.82M
est: 103.25M (-38.2%)
|
79.33M
est: 318.74M (-75.1%)
|
85.28M
est: 50.77M (+68.0%)
|
88.49M
est: 58.97M (+50.1%)
|
76.62M
est: 57.56M (+33.1%)
|
82.86M
est: 122.26M (-32.2%)
|
167.20M
108.23M – 250.60M
+36.8% YoY
|
196.82M
125.77M – 337.64M
+17.7% YoY
|
326.45M
316.36M – 336.54M
+65.9% YoY
|
489.95M
285.57M – 786.05M
+50.1% YoY
|
659.59M
384.44M – 1.06B
+34.6% YoY
|
| EPS |
-2.49
est: -1.88 (-32.4%)
|
-2.38
est: -2.34 (-1.6%)
|
-2.45
est: -2.75 (+10.8%)
|
2.73
est: 2.87 (-4.9%)
|
-2.58
est: -2.39 (-7.8%)
|
-2.98
est: -2.85 (-4.5%)
|
3.01
est: 3.89 (-22.7%)
|
-6.50
est: -6.19 (-5.0%)
|
-6.02
est: -5.23 (-15.0%)
|
-4.59
est: -4.73 (+2.9%)
|
-3.76
est: -3.30 (-13.8%)
|
-2.15
-3.64 – -0.54
+34.9% YoY
|
-2.81
-7.74 – 0.96
-30.5% YoY
|
-1.41
-2.51 – -0.35
+49.6% YoY
|
2.30
1.05 – 4.11
+262.7% YoY
|
6.30
2.88 – 11.25
+173.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-302.68M
OE per share TTM
-5.81
Owner's Yield
-92.37%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
96.2%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
63
Total invested
113.87M
Insider transactions (90d)
1
Beneficial owners (>5%)
28
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 6.57M | 15.40% | 6.48M | — | 6.57M | — | HC | Delaware | 2022-01-27 | ↗ |
| 2 | JPMORGAN CHASE & CO.13-2624428 | 5.00M | 11.70% | 4.28M | — | 5.00M | — | HC | Delaware | 2022-01-18 | ↗ |
| 3 | Jeremy C. Green | 4.24M | 9.60% | — | 4.24M | — | 4.24M | HC, IN | United Kingdom | 2023-11-17 | ↗ |
| 4 | Redmile Group, LLC | 4.24M | 9.60% | — | 4.24M | — | 4.24M | IA, OO | Delaware | 2023-11-17 | ↗ |
| 5 | The Vanguard Group - 23-1945930 | 3.42M | 9.27% | 69.5K | 4.1K | 3.35M | 69.4K | IA | Pennsylvania | 2020-02-12 | ↗ |
| 6 | Redmile Biopharma Investments III, L.P. | 2.52M | 5.70% | — | 2.52M | — | 2.52M | PN | Delaware | 2023-11-17 | ↗ |
| 7 | STATE STREET CORPORATION | 2.49M | 5.82% | — | 2.41M | — | 2.49M | HC | — | 2022-02-11 | ↗ |
| 8 | GIC Private Limited | 2.20M | 5.10% | 1.62M | 582.0K | 1.62M | 582.0K | CO | Republic of Singapore | 2023-04-07 | ↗ |
| 9 | 10 | 2.08M | 5.60% | 1.83M | 252.1K | 1.83M | 252.1K | CO | Republic of Singapore | 2020-03-06 | ↗ |
| 10 | 5.95%(1) | 2.03M | 5.95% | 2.03M | — | 2.03M | — | CO | Delaware | 2020-02-13 | ↗ |
| 11 | Abigail P. Johnson | 1.96M | 7.45% | — | — | 1.96M | — | IN | Delaware | 2016-06-30 | ↗ |
| 12 | FMR LLC | 1.96M | 7.45% | 1.3K | — | 1.96M | — | HC | Delaware | 2016-06-30 | ↗ |
| 13 | 2. | 1.91M | 5.11% | 463.7K | — | 463.7K | — | OO | — | 2021-02-12 | ↗ |
| 14 | RTW Investments, LP | 1.55M | 5.00% | — | 1.55M | — | 1.55M | IA, PN, OO | OR PLACE OF ORGANIZATION | 2017-10-05 | ↗ |
| 15 | Roderick Wong | 1.55M | 5.00% | — | 1.55M | — | 1.55M | HC, IN | OR PLACE OF ORGANIZATION | 2017-10-05 | ↗ |
| 16 | Select Biotechnology Portfolio | 1.50M | 5.69% | 1.50M | — | — | — | IV | Delaware | 2016-06-30 | ↗ |
| 17 | Deerfield Management Company, L.P. | 1.17M | 4.44% | — | 1.17M | — | — | PN | Delaware | 2016-02-16 | ↗ |
| 18 | Deerfield Mgmt III, L.P. | 1.17M | 4.44% | — | 1.17M | — | — | PN | Delaware | 2016-02-16 | ↗ |
| 19 | Deerfield Private Design Fund III, L.P. | 1.17M | 4.44% | — | 1.17M | — | — | PN | Delaware | 2016-02-16 | ↗ |
| 20 | James E. Flynn | 1.17M | 4.44% | — | 1.17M | — | — | IN | United States | 2016-02-16 | ↗ |
| 21 | Bruce F. Johnson | 440.2K | 5.02% | — | 10.83M | — | 10.83M | IN | Delaware | 2016-02-16 | ↗ |
| 22 | 10. | — | 0.00% | — | — | — | — | CO | Delaware | 2021-02-12 | ↗ |
| 23 | Brookside Capital Partners Fund, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2018-02-14 | ↗ |
| 24 | Brookside Capital Trading Fund, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2018-02-14 | ↗ |
| 25 | Deerfield International Master Fund, L.P. | — | 0.00% | — | — | — | — | PN | British Virgin Islands | 2016-02-16 | ↗ |
| 26 | Deerfield Mgmt, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2016-02-16 | ↗ |
| 27 | Deerfield Partners, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2016-02-16 | ↗ |
| 28 | Marsh & McLennan Companies, Inc. | — | 0.00% | 65.6K | 3.7K | 3.32M | 66.4K | HC | Pennsylvania | 2019-02-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
63
-121 vs prev Q
New positions
12
Closed positions
127
Increased
33
Reduced
17
Put/Call ratio
1.00
Calls held
49.5K
Puts held
49.5K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 149.0K +149.0K (+100.0%) | 2.15B +2.1B (+100.0%) | 0.29% +0.288 pp | 0.00% +0.003 pp | USD14.40 +0.0% | 1 qtrs NEW |
| 2 | BLACKROCK, INC. | 5.76M -614.1K (-9.6%) | 82.90M +21.4M (+34.8%) | 11.14% -1.237 pp | 0.00% +0.000 pp | USD10.05 +43.3% | 6 qtrs — |
| 3 | REDMILE GROUP, LLC | 4.37M -324.6K (-6.9%) | 62.91M +17.6M (+38.9%) | 8.45% -0.664 pp | 4.63% +0.226 pp | USD22.57 -36.2% | 36 qtrs — |
| 4 | JPMORGAN CHASE & CO | 3.55M -483.7K (-12.0%) | 51.17M +12.2M (+31.3%) | 6.87% -0.967 pp | 0.00% +0.001 pp | USD20.99 -31.4% | 42 qtrs — |
| 5 | VANGUARD GROUP INC | 3.37M +36.0K (+1.1%) | 48.59M +16.4M (+50.8%) | 6.53% +0.044 pp | 0.00% +0.000 pp | USD34.28 -58.0% | 42 qtrs — |
| 6 | STATE STREET CORP | 2.29M +301.9K (+15.2%) | 32.93M +13.8M (+71.9%) | 4.42% +0.569 pp | 0.00% +0.000 pp | USD20.59 -30.1% | 41 qtrs — |
| 7 | MORGAN STANLEY | 2.01M +310.5K (+18.2%) | 29.01M +12.6M (+76.4%) | 3.90% +0.588 pp | 0.00% +0.001 pp | USD13.21 +9.0% | 42 qtrs — |
| 8 | GOLDMAN SACHS GROUP INC | 1.79M -66.8K (-3.6%) | 25.71M +7.8M (+43.8%) | 3.45% -0.144 pp | 0.00% +0.001 pp | USD14.05 +2.5% | 39 qtrs — |
| 9 | AQR CAPITAL MANAGEMENT LLC | 1.36M +72.3K (+5.6%) | 19.61M +7.2M (+57.6%) | 2.63% +0.130 pp | 0.01% +0.002 pp | USD8.51 +69.2% | 16 qtrs — |
| 10 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 1.20M +100.0K (+9.1%) | 17.28M +6.7M (+62.8%) | 2.32% +0.185 pp | 0.86% +0.140 pp | USD13.75 +4.7% | 9 qtrs — |
| 11 | ASSENAGON ASSET MANAGEMENT S.A. | 1.16M +455.0K (+64.5%) | 16.71M +9.9M (+145.5%) | 2.24% +0.875 pp | 0.02% +0.014 pp | USD12.43 +15.8% | 9 qtrs — |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 1.15M +19.7K (+1.7%) | 16.50M +5.6M (+51.8%) | 2.22% +0.029 pp | 0.00% +0.000 pp | USD27.35 -47.3% | 41 qtrs — |
| 13 | 22NW, LP | 923.7K +— (+0.0%) | 13.30M +4.4M (+49.2%) | 1.79% -0.007 pp | 5.60% +1.399 pp | USD7.44 +93.5% | 4 qtrs — |
| 14 | DIMENSIONAL FUND ADVISORS LP | 903.9K -201.2K (-18.2%) | 13.01M +2.4M (+22.0%) | 1.75% -0.398 pp | 0.00% +0.000 pp | USD32.61 -55.8% | 31 qtrs — |
| 15 | NUVEEN, LLC | 658.5K +106.4K (+19.3%) | 9.48M +4.2M (+78.0%) | 1.27% +0.202 pp | 0.00% +0.001 pp | USD9.30 +54.8% | 4 qtrs — |
| 16 | PALE FIRE CAPITAL SE | 499.5K +243.9K (+95.4%) | 7.19M +4.7M (+191.6%) | 0.97% +0.470 pp | 0.48% +0.213 pp | USD11.85 +21.5% | 5 qtrs — |
| 17 | QUBE RESEARCH & TECHNOLOGIES LTD | 442.7K +157.9K (+55.4%) | 6.37M +3.6M (+131.9%) | 0.86% +0.303 pp | 0.01% +0.004 pp | USD11.50 +25.2% | 9 qtrs — |
| 18 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 391.5K -527.0 (-0.1%) | 5.64M +1.9M (+49.0%) | 0.76% -0.004 pp | 0.00% +0.000 pp | USD27.19 -47.0% | 41 qtrs — |
| 19 | ACADIAN ASSET MANAGEMENT LLC | 375.4K -23.7K (-5.9%) | 5.40M +1.6M (+40.4%) | 0.73% -0.049 pp | 0.01% +0.002 pp | USD8.37 +72.0% | 7 qtrs — |
| 20 | NORTHERN TRUST CORP | 373.7K -27.3K (-6.8%) | 5.38M +1.5M (+39.1%) | 0.72% -0.056 pp | 0.00% +0.000 pp | USD28.48 -49.4% | 41 qtrs — |
| 21 | STIFEL FINANCIAL CORP | 335.0K +14.6K (+4.6%) | 4.82M +1.7M (+56.0%) | 0.65% +0.026 pp | 0.00% +0.002 pp | USD12.63 +14.0% | 19 qtrs — |
| 22 | RENAISSANCE TECHNOLOGIES LLC | 333.1K +23.6K (+7.6%) | 4.80M +1.8M (+60.6%) | 0.64% +0.043 pp | 0.01% +0.004 pp | USD8.45 +70.4% | 5 qtrs — |
| 23 | BANK OF AMERICA CORP /DE/ | 300.6K -114.7K (-27.6%) | 4.33M +321.1K (+8.0%) | 0.58% -0.225 pp | 0.00% +0.000 pp | USD10.75 +34.0% | 42 qtrs — |
| 24 | HRT FINANCIAL LP | 299.9K +127.7K (+74.2%) | 4.32M +2.7M (+160.0%) | 0.58% +0.246 pp | 0.01% +0.008 pp | USD11.67 +23.4% | 6 qtrs — |
| 25 | VOSS CAPITAL, LLC | 295.0K -205.0K (-41.0%) | 4.25M -577.0K (-12.0%) | 0.57% -0.401 pp | 0.20% -0.030 pp | USD7.83 +83.9% | 5 qtrs — |
| 26 | GSK PLC | 271.5K +271.5K (+100.0%) | 3.91M +3.9M (+100.0%) | 0.53% +0.525 pp | 0.49% +0.489 pp | USD14.40 +0.0% | 1 qtrs NEW |
| 27 | FMR LLC | 266.1K +70.9K (+36.3%) | 3.83M +1.9M (+103.4%) | 0.51% +0.136 pp | 0.00% +0.000 pp | USD9.37 +53.7% | 42 qtrs — |
| 28 | TREXQUANT INVESTMENT LP | 250.7K -20.8K (-7.7%) | 3.61M +989.7K (+37.8%) | 0.49% -0.042 pp | 0.03% +0.005 pp | USD7.50 +92.0% | 13 qtrs — |
| 29 | AMERIPRISE FINANCIAL INC | 247.4K +5.3K (+2.2%) | 3.56M +1.2M (+52.5%) | 0.48% +0.008 pp | 0.00% +0.000 pp | USD29.62 -51.4% | 31 qtrs — |
| 30 | PANAGORA ASSET MANAGEMENT INC | 222.7K +15.9K (+7.7%) | 3.21M +1.2M (+60.7%) | 0.43% +0.029 pp | 0.01% +0.003 pp | USD18.35 -21.5% | 12 qtrs — |
| 31 | ARCHPOINT INVESTORS | 222.3K -1.3K (-0.6%) | 3.20M +1.0M (+48.4%) | 0.43% -0.004 pp | 0.76% +0.167 pp | USD31.93 -54.9% | 36 qtrs — |
| 32 | MILLENNIUM MANAGEMENT LLC | 214.7K +128.0K (+147.7%) | 3.09M +2.3M (+269.6%) | 0.42% +0.247 pp | 0.00% +0.001 pp | USD12.39 +16.2% | 27 qtrs — |
| 33 | UBS GROUP AG | 206.7K -55.7K (-21.2%) | 2.98M +444.0K (+17.5%) | 0.40% -0.110 pp | 0.00% +0.000 pp | USD12.63 +14.0% | 37 qtrs — |
| 34 | MOORE CAPITAL MANAGEMENT, LP | 200.0K +50.0K (+33.3%) | 2.88M +1.4M (+99.0%) | 0.39% +0.096 pp | 0.04% +0.022 pp | USD16.42 -12.3% | 8 qtrs — |
| 35 | JANE STREET GROUP, LLC | 196.5K -94.6K (-32.5%) | 2.83M +20.2K (+0.7%) | 0.38% -0.185 pp | 0.00% +0.000 pp | USD8.02 +79.6% | 22 qtrs — |
| 36 | DEUTSCHE BANK AG\ | 192.6K +1.5K (+0.8%) | 2.77M +929.5K (+50.4%) | 0.37% +0.002 pp | 0.00% +0.000 pp | USD19.83 -27.4% | 42 qtrs — |
| 37 | IEQ CAPITAL, LLC | 186.7K +27.9K (+17.5%) | 2.69M +1.2M (+75.4%) | 0.36% +0.053 pp | 0.01% +0.003 pp | USD9.07 +58.8% | 4 qtrs — |
| 38 | JUMP FINANCIAL, LLC | 178.0K +128.0K (+256.1%) | 2.56M +2.1M (+431.3%) | 0.34% +0.247 pp | 0.03% +0.026 pp | USD12.97 +11.0% | 11 qtrs — |
| 39 | BARCLAYS PLC | 164.4K +48.4K (+41.7%) | 2.37M +1.2M (+94.5%) | 0.32% +0.093 pp | 0.00% +0.000 pp | USD12.54 +14.8% | 38 qtrs — |
| 40 | INVESCO LTD. | 157.9K +8.0K (+5.4%) | 2.27M +827.5K (+57.2%) | 0.31% +0.014 pp | 0.00% +0.000 pp | USD15.42 -6.6% | 42 qtrs — |
| 41 | BANK OF NEW YORK MELLON CORP | 145.6K -4.5K (-3.0%) | 2.10M +647.8K (+44.7%) | 0.28% -0.010 pp | 0.00% +0.000 pp | USD40.93 -64.8% | 41 qtrs — |
| 42 | ADAR1 CAPITAL MANAGEMENT, LLC | 144.8K -60.6K (-29.5%) | 2.09M +103.6K (+5.2%) | 0.28% -0.119 pp | 0.15% -0.033 pp | USD8.80 +63.6% | 8 qtrs — |
| 43 | HUDSON BAY CAPITAL MANAGEMENT LP | 140.0K -60.0K (-30.0%) | 2.02M +86.0K (+4.5%) | 0.27% -0.118 pp | 0.01% +0.000 pp | USD11.58 +24.4% | 26 qtrs — |
| 44 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 133.6K +— (+0.0%) | 1.92M +634.4K (+49.2%) | 0.26% -0.001 pp | 0.03% +0.009 pp | USD9.65 +49.2% | 2 qtrs — |
| 45 | TWO SIGMA INVESTMENTS, LP | 129.9K -24.3K (-15.8%) | 1.87M +382.3K (+25.7%) | 0.25% -0.048 pp | 0.00% +0.000 pp | USD9.86 +46.0% | 10 qtrs — |
| 46 | DEKABANK DEUTSCHE GIROZENTRALE | 74.6K +— (+0.0%) | 1.80M +1.1M (+147.1%) | 0.14% -0.001 pp | 0.00% +0.002 pp | USD23.09 -37.6% | 22 qtrs — |
| 47 | ROYCE & ASSOCIATES LP | 119.0K +119.0K (+100.0%) | 1.71M +1.7M (+100.0%) | 0.23% +0.230 pp | 0.02% +0.017 pp | USD14.40 +0.0% | 1 qtrs NEW |
| 48 | PROPEL BIO MANAGEMENT, LLC | 116.9K +116.9K (+100.0%) | 1.68M +1.7M (+100.0%) | 0.23% +0.226 pp | 1.44% +1.437 pp | USD14.40 +0.0% | 1 qtrs NEW |
| 49 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 115.0K -3.8K (-3.2%) | 1.66M +509.5K (+44.4%) | 0.22% -0.008 pp | 0.00% +0.000 pp | USD9.40 +53.2% | 3 qtrs — |
| 50 | AMERICAN CENTURY COMPANIES INC | 113.1K -5.5K (-4.7%) | 1.63M +484.1K (+42.3%) | 0.22% -0.012 pp | 0.00% +0.000 pp | USD17.66 -18.5% | 16 qtrs — |
| 51 | HENNION & WALSH ASSET MANAGEMENT, INC. | 93.9K -47.8K (-33.7%) | 1.35M -15.3K (-1.1%) | 0.18% -0.094 pp | 0.05% -0.003 pp | USD21.00 -31.4% | 19 qtrs — |
| 52 | RAYMOND JAMES FINANCIAL INC | 86.0K -9.3K (-9.7%) | 1.24M +319.0K (+34.7%) | 0.17% -0.019 pp | 0.00% +0.000 pp | USD7.65 +88.2% | 5 qtrs — |
| 53 | WELLS FARGO & COMPANY/MN | 85.1K +11.6K (+15.8%) | 1.23M +516.0K (+72.7%) | 0.16% +0.022 pp | 0.00% +0.000 pp | USD14.85 -3.0% | 41 qtrs — |
| 54 | ACT CAPITAL MANAGEMENT, LLC | 82.5K +82.5K (+100.0%) | 1.19M +1.2M (+100.0%) | 0.16% +0.160 pp | 0.96% +0.961 pp | USD14.40 +0.0% | 1 qtrs NEW |
| 55 | CWM, LLC | 73.9K +5.8K (+8.6%) | 1.06M +407.0K (+61.9%) | 0.14% +0.011 pp | 0.00% +0.001 pp | USD8.79 +63.8% | 8 qtrs — |
| 56 | CERITY PARTNERS LLC | 71.5K +6.2K (+9.5%) | 1.03M +399.5K (+63.4%) | 0.14% +0.012 pp | 0.00% +0.001 pp | USD8.65 +66.5% | 4 qtrs — |
| 57 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 69.8K +59.6K (+584.3%) | 1.01M +906.7K (+921.2%) | 0.14% +0.115 pp | 0.00% +0.000 pp | USD13.71 +5.0% | 2 qtrs — |
| 58 | D. E. SHAW & CO., INC. | 68.4K +68.4K (+100.0%) | 984.8K +984.8K (+100.0%) | 0.13% +0.132 pp | 0.00% +0.001 pp | USD14.40 +0.0% | 1 qtrs NEW |
| 59 | RHUMBLINE ADVISERS | 65.8K -7.2K (-9.9%) | 947.9K +243.2K (+34.5%) | 0.13% -0.015 pp | 0.00% +0.000 pp | USD33.86 -57.5% | 39 qtrs — |
| 60 | ALLIANCEBERNSTEIN L.P. | 64.7K +— (+0.0%) | 932.1K +307.5K (+49.2%) | 0.13% -0.001 pp | 0.00% +0.000 pp | USD30.72 -53.1% | 35 qtrs — |
| 61 | MAN GROUP PLC | 63.6K -48.8K (-43.4%) | 915.4K -169.2K (-15.6%) | 0.12% -0.095 pp | 0.00% 0.000 pp | USD8.26 +74.3% | 6 qtrs — |
| 62 | RAFFERTY ASSET MANAGEMENT, LLC | 59.2K -6.7K (-10.1%) | 852.5K +216.9K (+34.1%) | 0.11% -0.013 pp | 0.00% +0.001 pp | USD8.32 +73.1% | 28 qtrs — |
| 63 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 55.6K +55.6K (+100.0%) | 800.8K +800.8K (+100.0%) | 0.11% +0.108 pp | 0.01% +0.006 pp | USD14.40 +0.0% | 1 qtrs NEW |
| 64 | MARINER, LLC | 55.4K +23.1K (+71.6%) | 797.0K +485.3K (+155.7%) | 0.11% +0.045 pp | 0.00% +0.001 pp | USD11.30 +27.4% | 3 qtrs — |
| 65 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 54.7K -488.0 (-0.9%) | 787.2K +253.6K (+47.5%) | 0.11% -0.001 pp | 0.00% +0.000 pp | USD10.98 +31.1% | 7 qtrs — |
| 66 | BRADLEY FOSTER & SARGENT INC/CT | 50.3K +147.0 (+0.3%) | 725.0K +240.6K (+49.7%) | 0.10% 0.000 pp | 0.01% +0.004 pp | USD8.23 +75.0% | 3 qtrs — |
| 67 | QUANTINNO CAPITAL MANAGEMENT LP | 50.0K +22.6K (+82.8%) | 719.9K +456.0K (+172.8%) | 0.10% +0.044 pp | 0.00% +0.001 pp | USD10.80 +33.3% | 4 qtrs — |
| 68 | TWO SIGMA ADVISERS, LP | 48.4K -21.7K (-31.0%) | 697.0K +20.5K (+3.0%) | 0.09% -0.043 pp | 0.00% +0.000 pp | USD11.35 +26.9% | 9 qtrs — |
| 69 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 44.4K +5.1K (+13.0%) | 630.0K +216.8K (+52.5%) | 0.09% +0.010 pp | 0.00% +0.000 pp | USD8.79 +63.8% | 4 qtrs — |
| 70 | SQUAREPOINT OPS LLC | 42.9K -163.5K (-79.2%) | 618.0K -1.4M (-69.0%) | 0.08% -0.318 pp | 0.00% -0.001 pp | USD8.41 +71.2% | 10 qtrs — |
| 71 | HSBC HOLDINGS PLC | 43.4K -32.9K (-43.1%) | 617.7K -127.3K (-17.1%) | 0.08% -0.064 pp | 0.00% 0.000 pp | USD10.04 +43.4% | 16 qtrs — |
| 72 | ALPS ADVISORS INC | 41.6K +16.9K (+68.2%) | 598.6K +360.1K (+151.0%) | 0.08% +0.032 pp | 0.00% +0.002 pp | USD10.72 +34.3% | 3 qtrs — |
| 73 | SG AMERICAS SECURITIES, LLC | 40.5K +13.9K (+52.4%) | 584.0K +327.0K (+127.2%) | 0.08% +0.027 pp | 0.00% 0.000 pp | USD11.28 +27.7% | 2 qtrs — |
| 74 | PRICE T ROWE ASSOCIATES INC /MD/ | 39.0K +3.0 (+0.0%) | 562.0K +185.0K (+49.1%) | 0.08% 0.000 pp | 0.00% +0.000 pp | USD24.17 -40.4% | 33 qtrs — |
| 75 | SIMPLIFY ASSET MANAGEMENT INC. | 38.0K +38.0K (+100.0%) | 547.2K +547.2K (+100.0%) | 0.07% +0.074 pp | 0.01% +0.009 pp | USD14.40 +0.0% | 1 qtrs NEW |
| 76 | STATE OF WISCONSIN INVESTMENT BOARD | 37.6K +17.9K (+90.5%) | 541.3K +350.9K (+184.3%) | 0.07% +0.034 pp | 0.00% +0.001 pp | USD12.94 +11.3% | 35 qtrs — |
| 77 | VICTORY CAPITAL MANAGEMENT INC | 37.3K +37.3K (+100.0%) | 536.9K +536.9K (+100.0%) | 0.07% +0.072 pp | 0.00% +0.000 pp | USD14.40 +0.0% | 1 qtrs NEW |
| 78 | VESTAL POINT CAPITAL, LP | 34.0K +34.0K (+100.0%) | 489.6K +489.6K (+100.0%) | 0.07% +0.066 pp | 0.02% +0.017 pp | USD14.40 +0.0% | 1 qtrs NEW |
| 79 | POINT72 ASSET MANAGEMENT, L.P. | 33.4K +33.4K (+100.0%) | 480.7K +480.7K (+100.0%) | 0.06% +0.065 pp | 0.00% +0.001 pp | USD14.40 +0.0% | 1 qtrs NEW |
| 80 | CREATIVE PLANNING | 33.0K +7.1K (+27.4%) | 475.5K +225.4K (+90.2%) | 0.06% +0.014 pp | 0.00% +0.000 pp | USD9.57 +50.5% | 4 qtrs — |
| 81 | LPL FINANCIAL LLC | 32.7K -2.1K (-6.1%) | 471.0K +135.0K (+40.2%) | 0.06% -0.004 pp | 0.00% +0.000 pp | USD7.61 +89.2% | 4 qtrs — |
| 82 | LOS ANGELES CAPITAL MANAGEMENT LLC | 34.1K -58.6K (-63.2%) | 436.6K -457.2K (-51.2%) | 0.07% -0.114 pp | 0.00% -0.002 pp | USD8.21 +75.4% | 3 qtrs — |
| 83 | CAPTION MANAGEMENT, LLC | 30.0K +— (+0.0%) | 432.0K +142.5K (+49.2%) | 0.06% 0.000 pp | 0.00% +0.001 pp | USD7.15 +101.4% | 4 qtrs — |
| 84 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 27.7K +947.0 (+3.5%) | 399.2K +140.8K (+54.5%) | 0.05% +0.002 pp | 0.00% +0.000 pp | USD8.42 +71.0% | 22 qtrs — |
| 85 | LION POINT CAPITAL, LP | 26.6K -31.2K (-53.9%) | 383.0K -174.2K (-31.3%) | 0.05% -0.061 pp | 1.98% -1.184 pp | USD16.74 -14.0% | 8 qtrs — |
| 86 | METLIFE INVESTMENT MANAGEMENT, LLC | 26.2K +— (+0.0%) | 377.9K +124.6K (+49.2%) | 0.05% 0.000 pp | 0.00% +0.001 pp | USD26.79 -46.2% | 33 qtrs — |
| 87 | DNB ASSET MANAGEMENT AS | 25.6K +7.7K (+42.9%) | 368.8K +195.9K (+113.2%) | 0.05% +0.015 pp | 0.00% +0.001 pp | USD10.91 +32.0% | 6 qtrs — |
| 88 | TUDOR INVESTMENT CORP ET AL | 24.3K +24.3K (+100.0%) | 350.1K +350.1K (+100.0%) | 0.05% +0.047 pp | 0.00% +0.001 pp | USD14.40 +0.0% | 1 qtrs NEW |
| 89 | MERCER GLOBAL ADVISORS INC /ADV | 24.1K +4.2K (+21.2%) | 347.6K +155.4K (+80.9%) | 0.05% +0.008 pp | 0.00% +0.000 pp | USD10.48 +37.4% | 2 qtrs — |
| 90 | MILITIA CAPITAL PARTNERS, LP | 23.6K +— (+0.0%) | 339.8K +112.1K (+49.2%) | 0.05% 0.000 pp | 0.13% +0.021 pp | USD8.21 +75.4% | 3 qtrs — |
| 91 | GRAHAM CAPITAL MANAGEMENT, L.P. | 22.6K -6.7K (-22.8%) | 325.9K +43.1K (+15.2%) | 0.04% -0.013 pp | 0.01% +0.003 pp | USD8.51 +69.2% | 7 qtrs — |
| 92 | BELVEDERE TRADING LLC | 22.5K +22.5K (+100.0%) | 324.0K +324.0K (+100.0%) | 0.04% +0.044 pp | 0.00% +0.000 pp | USD14.40 +0.0% | 1 qtrs NEW |
| 93 | PROFUND ADVISORS LLC | 22.3K +7.8K (+54.1%) | 320.4K +181.0K (+129.9%) | 0.04% +0.015 pp | 0.01% +0.005 pp | USD10.48 +37.4% | 12 qtrs — |
| 94 | CITADEL ADVISORS LLC | 21.7K -21.2K (-49.4%) | 312.5K -101.5K (-24.5%) | 0.04% -0.041 pp | 0.00% +0.000 pp | USD10.56 +36.4% | 32 qtrs — |
| 95 | INTECH INVESTMENT MANAGEMENT LLC | 21.4K +2.3K (+12.2%) | 307.7K +123.9K (+67.5%) | 0.04% +0.004 pp | 0.00% +0.001 pp | USD9.90 +45.5% | 6 qtrs — |
| 96 | MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. | 21.4K -2.3K (-9.6%) | 290.2K +61.9K (+27.1%) | 0.04% -0.005 pp | 0.00% +0.000 pp | USD19.64 -26.7% | 30 qtrs — |
| 97 | GREAT WEST LIFE ASSURANCE CO /CAN/ | 19.9K +5.3K (+36.8%) | 286.0K +143.0K (+100.0%) | 0.04% +0.010 pp | 0.00% +0.000 pp | USD13.00 +10.8% | 37 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
1
Shares acquired
—
Shares disposed
15.3K
Cash buys
—
Cash sales
1.00
Net activity
-15,309
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | PAKOLA STEVE | Officer | S-Sale | D | Common Stock | 15,309 | 11.02 | 168.7K | 232,617 | D | ↗ |
| 2026-03-10 | PAKOLA STEVE | Officer | S-Sale | D | Common Stock | 5,124 | 10.35 | 53.0K | 247,926 | D | ↗ |
| 2026-02-01 | PAKOLA STEVE | Officer | F-InKind | D | Common Stock | 5,267 | 11.16 | 58.8K | 253,050 | D | ↗ |
| 2026-02-01 | Christmas Patrick J. | Officer | F-InKind | D | Common Stock | 4,700 | 11.16 | 52.5K | 210,667 | D | ↗ |
| 2026-01-27 | Mills Kenneth T. | Director | M-Exempt | A | Common Stock | 225,000 | 13.09 | 2.95M | 707,871 | D | ↗ |
| 2026-01-06 | Simpson Curran | Director / Officer | A-Award | A | Stock Options (Right to buy) | 233,651 | 14.18 | 3.31M | 233,651 | D | ↗ |
| 2026-01-06 | PAKOLA STEVE | Officer | A-Award | A | Stock Options (Right to buy) | 35,402 | 14.18 | 502.0K | 35,402 | D | ↗ |
| 2026-01-06 | Malzahn Craig | Officer | A-Award | A | Stock Options (Right to buy) | 35,402 | 14.18 | 502.0K | 35,402 | D | ↗ |
| 2026-01-06 | Christmas Patrick J. | Officer | A-Award | A | Stock Options (Right to buy) | 39,650 | 14.18 | 562.2K | 39,650 | D | ↗ |
| 2026-01-06 | Chan Mitchell | Officer | A-Award | A | Stock Options (Right to buy) | 39,650 | 14.18 | 562.2K | 39,650 | D | ↗ |
| 2026-01-02 | Simpson Curran | Director / Officer | F-InKind | D | Common Stock | 18,559 | 14.40 | 267.2K | 197,603 | D | ↗ |
| 2026-01-02 | PAKOLA STEVE | Officer | F-InKind | D | Common Stock | 18,247 | 14.40 | 262.8K | 192,470 | D | ↗ |
| 2026-01-02 | Malzahn Craig | Officer | F-InKind | D | Common Stock | 1,238 | 14.40 | 17.8K | 16,347 | D | ↗ |
| 2026-01-02 | Christmas Patrick J. | Officer | F-InKind | D | Common Stock | 9,793 | 14.40 | 141.0K | 141,618 | D | ↗ |
| 2025-10-09 | Simpson Curran | Director / Officer | S-Sale | D | Common Stock | 20,811 | 12.62 | 262.6K | 216,162 | D | ↗ |
| 2025-09-29 | Simpson Curran | Director / Officer | S-Sale | D | Common Stock | 7,624 | 10.03 | 76.5K | 236,973 | D | ↗ |
| 2025-09-10 | Simpson Curran | Director / Officer | S-Sale | D | Common Stock | 7,734 | 10.02 | 77.5K | 244,597 | D | ↗ |
| 2025-09-01 | Malzahn Craig | Officer | F-InKind | D | Common Stock | 234 | 8.93 | 2.1K | 17,585 | D | ↗ |
| 2025-09-01 | Chan Mitchell | Officer | F-InKind | D | Common Stock | 4,901 | 8.93 | 43.8K | 53,968 | D | ↗ |
| 2025-08-01 | Christmas Patrick J. | Officer | F-InKind | D | Common Stock | 4,699 | 8.19 | 38.5K | 151,411 | D | ↗ |
| 2025-07-01 | Simpson Curran | Director / Officer | F-InKind | D | Common Stock | 4,701 | 8.23 | 38.7K | 252,331 | D | ↗ |
| 2025-05-30 | Zachary Jennifer | Director | A-Award | A | Common Stock | 7,768 | 0.00 | — | 22,064 | D | ↗ |
| 2025-05-30 | Tasse Daniel | Director | A-Award | A | Stock Options (Right to Buy) | 39,815 | 8.85 | 352.4K | 39,815 | D | ↗ |
| 2025-05-30 | STUMP DAVID C | Director | A-Award | A | Stock Options (Right to Buy) | 39,815 | 8.85 | 352.4K | 39,815 | D | ↗ |
| 2025-05-30 | Mills Kenneth T. | Director | A-Award | A | Stock Options (Right to Buy) | 39,815 | 8.85 | 352.4K | 39,815 | D | ↗ |
| 2025-05-30 | MIGAUSKY GEORGE V | Director | A-Award | A | Common Stock | 7,768 | 0.00 | — | 19,054 | D | ↗ |
| 2025-05-30 | KARABELAS ARGERIS N | Director | A-Award | A | Common Stock | 7,768 | 0.00 | — | 19,054 | D | ↗ |
| 2025-05-30 | Glucksmann Alexandra | Director | A-Award | A | Common Stock | 7,768 | 0.00 | — | 19,054 | D | ↗ |
| 2025-05-30 | Fox Allan M. | Director | A-Award | A | Common Stock | 7,768 | 0.00 | — | 19,054 | D | ↗ |
| 2025-05-30 | Bennett Jean | Director | A-Award | A | Common Stock | 7,768 | 0.00 | — | 19,054 | D | ↗ |
| 2025-05-12 | Mills Kenneth T. | Director | M-Exempt | D | Stock Options (Right to Buy) | 20,602 | 3.76 | 77.5K | 0 | D | ↗ |
| 2025-03-27 | Mills Kenneth T. | Director | M-Exempt | A | Common Stock | 30,752 | 3.76 | 115.6K | 475,103 | D | ↗ |
| 2025-03-13 | Malzahn Craig | Officer | — | — | Stock Options (Right to buy) | 19,130 | 22.25 | 425.6K | 0 | D | ↗ |
| 2025-02-01 | PAKOLA STEVE | Officer | F-InKind | D | Common Stock | 5,263 | 8.07 | 42.5K | 210,717 | D | ↗ |
| 2025-02-01 | Danos Olivier | Officer | F-InKind | D | Common Stock | 5,452 | 8.07 | 44.0K | 226,348 | D | ↗ |
| 2025-02-01 | Christmas Patrick J. | Officer | F-InKind | D | Common Stock | 4,700 | 8.07 | 37.9K | 156,110 | D | ↗ |
| 2025-01-02 | Simpson Curran | Director / Officer | A-Award | A | Stock Options (Right to buy) | 476,606 | 7.86 | 3.75M | 476,606 | D | ↗ |
| 2025-01-02 | PAKOLA STEVE | Officer | A-Award | A | Stock Options (Right to buy) | 103,698 | 7.86 | 815.1K | 103,698 | D | ↗ |
| 2025-01-02 | Danos Olivier | Officer | A-Award | A | Stock Options (Right to buy) | 95,721 | 7.86 | 752.4K | 95,721 | D | ↗ |
| 2025-01-02 | Christmas Patrick J. | Officer | F-InKind | D | Common Stock | 11,395 | 7.73 | 88.1K | 160,810 | D | ↗ |
| 2025-01-02 | Chan Mitchell | Officer | A-Award | A | Stock Options (Right to buy) | 62,547 | 7.86 | 491.6K | 62,547 | D | ↗ |
| 2024-10-01 | KARABELAS ARGERIS N | Director | M-Exempt | A | Common Stock | 10,000 | 3.76 | 37.6K | 21,286 | D | ↗ |
| 2024-09-16 | Chan Mitchell | Officer | A-Award | A | Common Stock | 58,869 | 0.00 | — | 58,869 | — | ↗ |
| 2024-09-03 | KARABELAS ARGERIS N | Director | S-Sale | D | Common Stock | 9,300 | 11.50 | 107.0K | 11,986 | — | ↗ |
| 2024-08-08 | Mills Kenneth T. | Director | M-Exempt | A | Common Stock | 36,316 | 0.85 | 30.9K | 444,351 | — | ↗ |
| 2024-08-01 | Simpson Curran | Director / Officer | S-Sale | D | Common Stock | 100 | 15.00 | 1.5K | 170,037 | — | ↗ |
| 2024-08-01 | PAKOLA STEVE | Officer | A-Award | A | Common Stock | 58,386 | 0.00 | — | 165,578 | — | ↗ |
| 2024-08-01 | KARABELAS ARGERIS N | Director | S-Sale | D | Common Stock | 9,600 | 13.45 | 129.1K | 11,786 | — | ↗ |
| 2024-08-01 | Danos Olivier | Officer | A-Award | A | Common Stock | 58,867 | 0.00 | — | 185,083 | — | ↗ |
| 2024-08-01 | Christmas Patrick J. | Officer | A-Award | A | Common Stock | 56,446 | 0.00 | — | 172,205 | — | ↗ |
| 2024-07-29 | Simpson Curran | Director / Officer | S-Sale | D | Common Stock | 9,648 | 15.04 | 145.1K | 170,137 | — | ↗ |
| 2024-07-29 | KARABELAS ARGERIS N | Director | S-Sale | D | Common Stock | 11,000 | 15.05 | 165.5K | 11,286 | — | ↗ |
| 2024-07-25 | Mills Kenneth T. | Director | M-Exempt | A | Common Stock | 15,369 | 3.76 | 57.8K | 423,404 | — | ↗ |
| 2024-07-24 | Mills Kenneth T. | Director | M-Exempt | A | Common Stock | 12,221 | 3.76 | 46.0K | 420,256 | — | ↗ |
| 2024-07-17 | Mills Kenneth T. | Director | S-Sale | D | Common Stock | 2,210 | 13.77 | 30.4K | 408,035 | — | ↗ |
| 2024-07-16 | Mills Kenneth T. | Director | S-Sale | D | Common Stock | 200 | 13.76 | 2.8K | 408,035 | — | ↗ |
| 2024-07-01 | Simpson Curran | Director / Officer | A-Award | A | Stock Options (Right to Buy) | 272,189 | 11.07 | 3.01M | 272,189 | — | ↗ |
| 2024-07-01 | KARABELAS ARGERIS N | Director | M-Exempt | D | Stock Options (Right to Buy) | 10,000 | 3.76 | 37.6K | 30,000 | — | ↗ |
| 2024-06-28 | Danos Olivier | Officer | A-Award | A | Common Stock | 1,363 | 9.95 | 13.6K | 126,216 | — | ↗ |
| 2024-05-31 | Zachary Jennifer | Director | A-Award | A | Common Stock | 4,790 | 0.00 | — | 14,296 | — | ↗ |
| 2024-05-31 | Tasse Daniel | Director | A-Award | A | Common Stock | 4,790 | 0.00 | — | 11,286 | — | ↗ |
| 2024-05-31 | STUMP DAVID C | Director | A-Award | A | Stock Options (Right to Buy) | 24,454 | 14.35 | 350.9K | 24,454 | — | ↗ |
| 2024-05-31 | MIGAUSKY GEORGE V | Director | A-Award | A | Common Stock | 4,790 | 0.00 | — | 11,286 | — | ↗ |
| 2024-05-31 | KARABELAS ARGERIS N | Director | A-Award | A | Common Stock | 4,790 | 0.00 | — | 11,286 | — | ↗ |
| 2024-05-31 | Glucksmann Alexandra | Director | A-Award | A | Common Stock | 4,790 | 0.00 | — | 11,286 | — | ↗ |
| 2024-05-31 | Fox Allan M. | Director | A-Award | A | Common Stock | 4,790 | 0.00 | — | 11,286 | — | ↗ |
| 2024-05-31 | Bennett Jean | Director | A-Award | A | Common Stock | 4,790 | 0.00 | — | 11,286 | — | ↗ |
| 2024-05-14 | Mills Kenneth T. | Director / Officer | S-Sale | D | Common Stock | 15,000 | 15.81 | 237.2K | 408,035 | — | ↗ |
| 2024-04-15 | Mills Kenneth T. | Director / Officer | M-Exempt | A | Common Stock | 15,000 | 3.76 | 56.4K | 423,035 | — | ↗ |
| 2024-03-19 | Vasista Vittal | Officer | M-Exempt | A | Common Stock | 20,041 | 3.76 | 75.4K | 246,534 | — | ↗ |
| 2024-03-14 | Mills Kenneth T. | Director / Officer | M-Exempt | A | Common Stock | 15,000 | 3.76 | 56.4K | 423,035 | — | ↗ |
| 2024-03-05 | PAKOLA STEVE | Officer | M-Exempt | A | Common Stock | 12,878 | 22.25 | 286.5K | 120,070 | — | ↗ |
| 2024-02-14 | Mills Kenneth T. | Director / Officer | S-Sale | D | Common Stock | 4,652 | 16.47 | 76.6K | 418,383 | — | ↗ |
| 2024-01-16 | Mills Kenneth T. | Director / Officer | M-Exempt | A | Common Stock | 45,000 | 3.76 | 169.2K | 453,035 | — | ↗ |
| 2024-01-03 | PAKOLA STEVE | Officer | S-Sale | D | Common Stock | 17,237 | 17.39 | 299.8K | 107,192 | — | ↗ |
| 2024-01-02 | Vasista Vittal | Officer | A-Award | A | Stock Options (Right to buy) | 76,313 | 18.34 | 1.40M | 76,313 | — | ↗ |
| 2024-01-02 | Simpson Curran | Officer | A-Award | A | Stock Options (Right to buy) | 61,050 | 18.34 | 1.12M | 61,050 | — | ↗ |
| 2024-01-02 | PAKOLA STEVE | Officer | A-Award | A | Stock Options (Right to buy) | 50,875 | 18.34 | 933.0K | 50,875 | — | ↗ |
| 2024-01-02 | Mills Kenneth T. | Director / Officer | A-Award | A | Stock Options (Right to buy) | 305,250 | 18.34 | 5.60M | 305,250 | — | ↗ |
| 2024-01-02 | Danos Olivier | Officer | F-InKind | D | Common Stock | 8,410 | 17.95 | 151.0K | 86,391 | — | ↗ |
| 2024-01-02 | Christmas Patrick J. | Officer | A-Award | A | Stock Options (Right to buy) | 54,945 | 18.34 | 1.01M | 54,945 | — | ↗ |
| 2023-12-19 | Mills Kenneth T. | Director / Officer | M-Exempt | A | Common Stock | 43,500 | 3.76 | 163.6K | 398,789 | — | ↗ |
| 2023-06-30 | Danos Olivier | Officer | A-Award | A | Common Stock | 1,123 | 16.99 | 19.1K | 94,801 | — | ↗ |
| 2023-06-02 | Zachary Jennifer | Director | A-Award | A | Stock Options (Right to Buy) | 17,892 | 19.72 | 352.8K | 17,892 | — | ↗ |
| 2023-06-02 | Tasse Daniel | Director | A-Award | A | Stock Options (Right to Buy) | 17,892 | 19.72 | 352.8K | 17,892 | — | ↗ |
| 2023-06-02 | STUMP DAVID C | Director | A-Award | A | Common Stock | 3,486 | 0.00 | — | 6,496 | — | ↗ |
| 2023-06-02 | MIGAUSKY GEORGE V | Director | A-Award | A | Common Stock | 3,486 | 0.00 | — | 6,496 | — | ↗ |
| 2023-06-02 | KARABELAS ARGERIS N | Director | A-Award | A | Stock Options (Right to Buy) | 17,892 | 19.72 | 352.8K | 17,892 | — | ↗ |
| 2023-06-02 | Glucksmann Alexandra | Director | A-Award | A | Stock Options (Right to Buy) | 17,892 | 19.72 | 352.8K | 17,892 | — | ↗ |
| 2023-06-02 | Fox Allan M. | Director | A-Award | A | Common Stock | 3,486 | 0.00 | — | 6,496 | — | ↗ |
| 2023-06-02 | Bennett Jean | Director | A-Award | A | Stock Options (Right to Buy) | 17,892 | 19.72 | 352.8K | 17,892 | — | ↗ |
| 2023-05-31 | Vasista Vittal | Officer | M-Exempt | A | Common Stock | 35,000 | 0.85 | 29.8K | 215,001 | — | ↗ |
| 2023-01-03 | Vasista Vittal | Director / Officer | A-Award | A | Stock Options (Right to buy) | 66,233 | 0.00 | — | 66,233 | — | ↗ |
| 2023-01-03 | Simpson Curran | Director / Officer | F-InKind | D | Common Stock | 2,076 | 22.68 | 47.1K | 25,040 | — | ↗ |
| 2023-01-03 | PAKOLA STEVE | Director / Officer | S-Sale | D | Common Stock | 3,138 | 22.17 | 69.6K | 12,175 | — | ↗ |
| 2023-01-03 | Mills Kenneth T. | Director | F-InKind | D | Common Stock | 9,308 | 22.68 | 211.1K | 300,536 | — | ↗ |
| 2023-01-03 | Danos Olivier | Director / Officer | A-Award | A | Stock Options (Right to buy) | 52,986 | 0.00 | — | 52,986 | — | ↗ |
| 2023-01-03 | Christmas Patrick J. | Director / Officer | F-InKind | D | Common Stock | 1,843 | 22.68 | 41.8K | 21,097 | — | ↗ |
| 2022-08-30 | Vasista Vittal | Director / Officer | S-Sale | D | Common Stock | 2,400 | 30.24 | 72.6K | 135,160 | — | ↗ |
| 2022-08-04 | Vasista Vittal | Officer | S-Sale | D | Common Stock | 400 | 35.00 | 14.0K | 154,840 | — | ↗ |
| 2022-08-01 | Vasista Vittal | Director / Officer | S-Sale | D | Common Stock | 2,400 | 31.26 | 75.0K | 155,240 | — | ↗ |
| 2022-07-13 | Vasista Vittal | Officer | S-Sale | D | Common Stock | 4,332 | 30.01 | 130.0K | 158,108 | — | ↗ |
| 2022-06-30 | Danos Olivier | Officer | A-Award | A | Common Stock | 728 | 21.00 | 15.3K | 93,678 | — | ↗ |
| 2022-06-03 | Zachary Jennifer | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-03 | Tasse Daniel | Director | A-Award | A | Stock Option (Right to Buy) | 15,324 | 22.84 | 350.0K | 15,324 | — | ↗ |
| 2022-06-03 | STUMP DAVID C | Director | A-Award | A | Common Stock | 3,010 | 0.00 | — | 3,010 | — | ↗ |
| 2022-06-03 | MIGAUSKY GEORGE V | Director | A-Award | A | Stock Option (Right to Buy) | 15,324 | 0.00 | — | 15,324 | — | ↗ |
| 2022-06-03 | KARABELAS ARGERIS N | Director | A-Award | A | Common Stock | 3,010 | 0.00 | — | 3,010 | — | ↗ |
| 2022-06-03 | Glucksmann Alexandra | Director | A-Award | A | Stock Option (Right to Buy) | 15,324 | 0.00 | — | 15,324 | — | ↗ |
| 2022-06-03 | Fox Allan M. | Director | A-Award | A | Common Stock | 3,010 | 0.00 | — | 3,010 | — | ↗ |
| 2022-06-03 | Bennett Jean | Director | A-Award | A | Stock Option (Right to Buy) | 15,324 | 0.00 | — | 15,324 | — | ↗ |
| 2022-01-20 | Vasista Vittal | — | M-Exempt | A | Common Stock | 29,900 | 0.85 | 25.4K | 162,440 | — | ↗ |
| 2022-01-03 | Vasista Vittal | — | A-Award | A | Common Stock | 8,900 | 0.00 | — | 132,540 | — | ↗ |
| 2022-01-03 | Simpson Curran | — | A-Award | A | Common Stock | 10,700 | 0.00 | — | 27,116 | — | ↗ |
| 2022-01-03 | PAKOLA STEVE | — | A-Award | A | Stock Option (Right to Buy) | 42,500 | 34.31 | 1.46M | 42,500 | — | ↗ |
| 2022-01-03 | Mills Kenneth T. | — | A-Award | A | Common Stock | 35,796 | 0.00 | — | 309,844 | — | ↗ |
| 2022-01-03 | Danos Olivier | — | A-Award | A | Common Stock | 10,700 | 0.00 | — | 29,078 | — | ↗ |
| 2022-01-03 | Christmas Patrick J. | — | A-Award | A | Stock Option (Right to Buy) | 37,400 | 34.31 | 1.28M | 37,400 | — | ↗ |
| 2022-01-01 | Simpson Curran | — | F-InKind | D | Common Stock | 1,332 | 32.70 | 43.6K | 16,416 | — | ↗ |
| 2022-01-01 | PAKOLA STEVE | — | F-InKind | D | Common Stock | 1,152 | 32.70 | 37.7K | 9,848 | — | ↗ |
| 2022-01-01 | Mills Kenneth T. | — | F-InKind | D | Common Stock | 3,636 | 32.70 | 118.9K | 274,048 | — | ↗ |
| 2022-01-01 | Danos Olivier | — | F-InKind | D | Common Stock | 1,221 | 32.70 | 39.9K | 18,378 | — | ↗ |
| 2022-01-01 | Christmas Patrick J. | — | F-InKind | D | Common Stock | 1,332 | 32.70 | 43.6K | 15,040 | — | ↗ |
| 2021-12-31 | Danos Olivier | — | A-Award | A | Common Stock | 1 | 27.80 | 27.80 | 19,599 | — | ↗ |
| 2021-12-23 | Fox Allan M. | — | S-Sale | D | Common Stock | 44,908 | 34.92 | 1.57M | 1,536,304 | — | ↗ |
| 2021-12-22 | Fox Allan M. | — | S-Sale | D | Common Stock | 61,638 | 34.40 | 2.12M | 1,581,212 | — | ↗ |
| 2021-12-02 | Mills Kenneth T. | — | G-Gift | D | Common Stock | 3,300 | 0.00 | — | 277,684 | — | ↗ |
| 2021-11-08 | Mills Kenneth T. | — | M-Exempt | A | Common Stock | 1,500 | 3.76 | 5.6K | 282,484 | — | ↗ |
| 2021-09-27 | Mills Kenneth T. | — | S-Sale | D | Common Stock | 1,500 | 42.19 | 63.3K | 280,984 | — | ↗ |
| 2021-09-17 | Fox Allan M. | Director | S-Sale | D | Common Stock | 48,233 | 45.04 | 2.17M | 1,364,309 | — | ↗ |
| 2021-09-14 | Mills Kenneth T. | — | M-Exempt | A | Common Stock | 1,854 | 0.85 | 1.6K | 315,984 | — | ↗ |
| 2021-09-13 | Mills Kenneth T. | — | M-Exempt | A | Common Stock | 3,000 | 3.76 | 11.3K | 283,984 | — | ↗ |
| 2021-09-03 | MIGAUSKY GEORGE V | — | A-Award | A | Stock Option (Right to Buy) | 20,000 | 34.98 | 699.6K | 20,000 | — | ↗ |
| 2021-09-03 | Bennett Jean | — | A-Award | A | Stock Option (Right to Buy) | 20,000 | 34.98 | 699.6K | 20,000 | — | ↗ |
| 2021-07-27 | Vasista Vittal | — | M-Exempt | A | Common Stock | 10,000 | 0.85 | 8.5K | 123,640 | — | ↗ |
| 2021-06-30 | Danos Olivier | — | A-Award | A | Common Stock | 555 | 33.02 | 18.3K | 19,598 | — | ↗ |
| 2021-06-25 | Mills Kenneth T. | — | M-Exempt | A | Common Stock | 1,500 | 3.76 | 5.6K | 282,484 | — | ↗ |
| 2021-06-24 | Mills Kenneth T. | — | M-Exempt | A | Common Stock | 4,500 | 3.76 | 16.9K | 285,484 | — | ↗ |
| 2021-06-04 | Tasse Daniel | — | A-Award | A | Stock Option (Right to Buy) | 10,000 | 35.52 | 355.2K | 10,000 | — | ↗ |
| 2021-06-04 | STUMP DAVID C | — | A-Award | A | Stock Option (Right to Buy) | 10,000 | 35.52 | 355.2K | 10,000 | — | ↗ |
| 2021-06-04 | KARABELAS ARGERIS N | — | A-Award | A | Stock Option (Right to Buy) | 10,000 | 35.52 | 355.2K | 10,000 | — | ↗ |
| 2021-06-04 | Glucksmann Alexandra | — | A-Award | A | Stock Option (Right to Buy) | 10,000 | 35.52 | 355.2K | 10,000 | — | ↗ |
| 2021-06-04 | Fox Allan M. | — | A-Award | A | Stock Option (Right to Buy) | 10,000 | 35.52 | 355.2K | 10,000 | — | ↗ |
| 2021-06-04 | BESHAR LUKE M | — | A-Award | A | Stock Option (Right to Buy) | 10,000 | 35.52 | 355.2K | 10,000 | — | ↗ |
| 2021-06-04 | Abdun-Nabi Daniel | — | A-Award | A | Stock Option (Right to Buy) | 10,000 | 35.52 | 355.2K | 10,000 | — | ↗ |
| 2021-02-25 | Mills Kenneth T. | — | M-Exempt | A | Common Stock | 1,500 | 0.85 | 1.3K | 282,484 | — | ↗ |
| 2021-02-12 | Christmas Patrick J. | — | M-Exempt | A | Common Stock | 4,701 | 12.10 | 56.9K | 21,073 | — | ↗ |
| 2021-02-08 | Christmas Patrick J. | — | M-Exempt | A | Common Stock | 1,300 | 12.10 | 15.7K | 17,672 | — | ↗ |
| 2021-02-02 | Christmas Patrick J. | — | S-Sale | D | Common Stock | 9,500 | 44.77 | 425.3K | 16,872 | — | ↗ |
| 2021-01-25 | Mills Kenneth T. | — | M-Exempt | A | Common Stock | 6,500 | 0.85 | 5.5K | 287,484 | — | ↗ |
| 2021-01-15 | Vasista Vittal | — | S-Sale | D | Common Stock | 252 | 50.04 | 12.6K | 113,640 | — | ↗ |
| 2021-01-14 | Vasista Vittal | — | S-Sale | D | Common Stock | 11,093 | 50.03 | 555.0K | 113,892 | — | ↗ |
| 2021-01-14 | Simpson Curran | — | M-Exempt | A | Common Stock | 10,372 | 35.80 | 371.3K | 29,360 | — | ↗ |
| 2021-01-12 | Vasista Vittal | — | S-Sale | D | Common Stock | 4,200 | 50.01 | 210.0K | 124,985 | — | ↗ |
| 2021-01-12 | Simpson Curran | — | M-Exempt | D | Stock Option (Right to Buy) | 1,700 | 19.50 | 33.2K | 1,240 | — | ↗ |
| 2021-01-12 | Christmas Patrick J. | — | M-Exempt | D | Stock Option (Right to Buy) | 1,378 | 19.50 | 26.9K | 641 | — | ↗ |
| 2021-01-11 | Christmas Patrick J. | — | M-Exempt | D | Stock Option (Right to Buy) | 2,622 | 19.50 | 51.1K | 2,019 | — | ↗ |
| 2021-01-08 | Vasista Vittal | — | S-Sale | D | Common Stock | 573 | 48.15 | 27.6K | 129,185 | — | ↗ |
| 2021-01-08 | Christmas Patrick J. | — | M-Exempt | D | Employee Stock Option (Right to Buy) | 10,000 | 12.10 | 121.0K | 29,931 | — | ↗ |
| 2021-01-07 | Vasista Vittal | — | S-Sale | D | Common Stock | 10,998 | 50.00 | 549.9K | 134,426 | — | ↗ |
| 2021-01-07 | Simpson Curran | — | M-Exempt | A | Common Stock | 5,185 | 19.50 | 101.1K | 22,933 | — | ↗ |
| 2021-01-07 | Mills Kenneth T. | — | M-Exempt | A | Common Stock | 1,500 | 0.85 | 1.3K | 283,484 | — | ↗ |
| 2021-01-04 | Vasista Vittal | — | A-Award | A | Stock Option (Right to Buy) | 56,200 | 44.97 | 2.53M | 56,200 | — | ↗ |
| 2021-01-04 | Simpson Curran | — | A-Award | A | Common Stock | 13,800 | 0.00 | — | 17,748 | — | ↗ |
| 2021-01-04 | PAKOLA STEVE | — | A-Award | A | Common Stock | 11,000 | 0.00 | — | 11,000 | — | ↗ |
| 2021-01-04 | Mills Kenneth T. | — | A-Award | A | Common Stock | 40,984 | 0.00 | — | 281,984 | — | ↗ |
| 2021-01-04 | Danos Olivier | — | A-Award | A | Stock Option (Right to Buy) | 52,500 | 44.97 | 2.36M | 52,500 | — | ↗ |
| 2021-01-04 | Christmas Patrick J. | — | A-Award | A | Stock Option (Right to Buy) | 62,500 | 44.97 | 2.81M | 62,500 | — | ↗ |
| 2020-12-28 | Mills Kenneth T. | — | S-Sale | D | Common Stock | 4,647 | 48.47 | 225.2K | 242,853 | — | ↗ |
| 2020-12-24 | Vasista Vittal | — | S-Sale | D | Common Stock | 3,376 | 50.00 | 168.8K | 133,024 | — | ↗ |
| 2020-12-23 | Vasista Vittal | — | S-Sale | D | Common Stock | 21,124 | 50.01 | 1.06M | 136,400 | — | ↗ |
| 2020-12-23 | Mills Kenneth T. | — | M-Exempt | A | Common Stock | 4,500 | 0.85 | 3.8K | 245,500 | — | ↗ |
| 2020-12-16 | Mills Kenneth T. | — | S-Sale | D | Common Stock | 15,000 | 45.00 | 675.0K | 241,000 | — | ↗ |
| 2020-12-11 | Vasista Vittal | — | S-Sale | D | Common Stock | 14,916 | 40.17 | 599.2K | 157,524 | — | ↗ |
| 2020-12-10 | Vasista Vittal | — | S-Sale | D | Common Stock | 22,584 | 40.06 | 904.7K | 172,440 | — | ↗ |
| 2020-12-10 | Mills Kenneth T. | — | S-Sale | D | Common Stock | 4,500 | 40.00 | 180.0K | 241,000 | — | ↗ |
| 2020-08-06 | Fox Allan M. | Director | G-Gift | D | Common Stock | 90,000 | 0.00 | — | 1,324,110 | — | ↗ |
| 2020-07-27 | Fox Allan M. | Director | G-Gift | D | Common Stock | 225,000 | 0.00 | — | 1,414,110 | — | ↗ |
| 2020-07-15 | Vasista Vittal | — | S-Sale | D | Common Stock | 14,950 | 40.10 | 599.5K | 195,024 | — | ↗ |
| 2020-06-30 | Danos Olivier | — | A-Award | A | Common Stock | 641 | 31.31 | 20.1K | 7,443 | — | ↗ |
| 2020-05-29 | Tasse Daniel | — | A-Award | A | Stock Option (Right to Buy) | 10,000 | 37.66 | 376.6K | 10,000 | — | ↗ |
| 2020-05-29 | STUMP DAVID C | — | A-Award | A | Stock Option (Right to Buy) | 10,000 | 37.66 | 376.6K | 10,000 | — | ↗ |
| 2020-05-29 | KARABELAS ARGERIS N | — | A-Award | A | Stock Option (Right to Buy) | 10,000 | 37.66 | 376.6K | 10,000 | — | ↗ |
| 2020-05-29 | HAYDEN DONALD J JR | — | A-Award | A | Stock Option (Right to Buy) | 10,000 | 37.66 | 376.6K | 10,000 | — | ↗ |
| 2020-05-29 | Glucksmann Alexandra | — | A-Award | A | Stock Option (Right to Buy) | 10,000 | 37.66 | 376.6K | 10,000 | — | ↗ |
| 2020-05-29 | Fox Allan M. | — | A-Award | A | Stock Option (Right to Buy) | 10,000 | 37.66 | 376.6K | 10,000 | — | ↗ |
| 2020-05-29 | BESHAR LUKE M | — | A-Award | A | Stock Option (Right to Buy) | 10,000 | 37.66 | 376.6K | 10,000 | — | ↗ |
| 2020-05-29 | Abdun-Nabi Daniel | — | A-Award | A | Stock Option (Right to Buy) | 10,000 | 37.66 | 376.6K | 10,000 | — | ↗ |
| 2020-05-11 | Vasista Vittal | — | M-Exempt | A | Common Stock | 500 | 13.09 | 6.5K | 207,215 | — | ↗ |
| 2020-05-08 | Vasista Vittal | — | M-Exempt | A | Common Stock | 2,500 | 13.09 | 32.7K | 213,715 | — | ↗ |
| 2020-04-24 | Vasista Vittal | — | S-Sale | D | Common Stock | 12,000 | 40.11 | 481.3K | 211,215 | — | ↗ |
| 2020-04-23 | Vasista Vittal | — | M-Exempt | D | Employee Stock Option (Right to Buy) | 3,000 | 13.09 | 39.3K | 23,374 | — | ↗ |
| 2020-03-31 | Vasista Vittal | — | M-Exempt | A | Common Stock | 10,000 | 0.85 | 8.5K | 220,215 | — | ↗ |
| 2020-02-11 | Simpson Curran | — | M-Exempt | D | Stock Option (Right to Buy) | 6,633 | 22.00 | 145.9K | 0 | — | ↗ |
| 2020-02-10 | Vasista Vittal | — | M-Exempt | D | Employee Stock Option (Right to Buy) | 3,000 | 13.09 | 39.3K | 26,374 | — | ↗ |
| 2020-02-10 | Simpson Curran | — | M-Exempt | D | Stock Option (Right to Buy) | 14,928 | 22.00 | 328.4K | 6,633 | — | ↗ |
| 2020-02-10 | HAYDEN DONALD J JR | — | M-Exempt | A | Common Stock | 24,800 | 0.85 | 21.1K | 24,800 | — | ↗ |
| 2020-02-05 | Vasista Vittal | — | S-Sale | D | Common Stock | 300 | 50.00 | 15.0K | 222,021 | — | ↗ |
| 2020-02-05 | Simpson Curran | — | S-Sale | D | Common Stock | 5,637 | 50.00 | 281.9K | 22,648 | — | ↗ |
| 2020-02-05 | HAYDEN DONALD J JR | — | S-Sale | D | Common Stock | 2,000 | 50.00 | 100.0K | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-456.7K
Shares Outstanding
51.62M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Curran Simpson President and Chief Executive Officer | 665.5K | — | 777.4K | 2.35M | 387.3K | 20.1K | 4.20M | 74.46% | ↗ |
| 2 | 2025 | Patrick J. Christmas EVP, Chief Strategy and Legal Officer | 520.9K | 200.0K | — | 1.10M | 203.7K | 20.1K | 2.04M | 53.73% | ↗ |
| 3 | 2025 | Stephen Pakola, M.D. EVP, Chief Medical Officer | 544.0K | — | 505.3K | 509.2K | 220.9K | 20.1K | 1.80M | 56.38% | ↗ |
| 4 | 2024 | Kenneth T. Mills Former President and CEO | 341.0K | — | 1.18M | 3.49M | 406.1K | 94.7K | 5.51M | 84.71% | ↗ |
| 5 | 2024 | Curran Simpson President and Chief Executive Officer | 571.7K | — | 1.33M | 2.57M | 289.7K | 19.8K | 4.78M | 81.58% | ↗ |
| 6 | 2024 | Curran Simpson President and CEO | 571.7K | — | 1.33M | 2.57M | 289.7K | 19.8K | 4.78M | 81.58% | ↗ |
| 7 | 2024 | Mitchell Chan EVP, Chief Financial Officer | 141.3K | — | 750.0K | 2.25M | 56.9K | 7.0K | 3.21M | 93.59% | ↗ |
| 8 | 2024 | Olivier Danos, Ph.D. EVP, Chief Scientific Officer | 522.3K | — | 1.49M | 697.9K | 206.3K | 41.4K | 2.96M | 73.96% | ↗ |
| 9 | 2024 | Patrick J. Christmas EVP, Chief Strategy and Legal Officer | 500.9K | — | 1.39M | 628.1K | 202.9K | 19.8K | 2.74M | 73.57% | ↗ |
| 10 | 2024 | Stephen Pakola, M.D. EVP, Chief Medical Officer | 518.1K | — | 1.36M | 581.6K | 212.4K | 19.8K | 2.70M | 72.18% | ↗ |
| 11 | 2024 | Vit Vasista Former EVP, Chief Financial Officer | 357.7K | — | 293.9K | 872.4K | 150.0K | 552.9K | 2.23M | 52.37% | ↗ |
| 12 | 2023 | Kenneth T. Mills Former President and CEO | 676.8K | — | 1.22M | 3.70M | 304.6K | 19.0K | 5.92M | 83.09% | ↗ |
| 13 | 2023 | Kenneth T. Mills President and CEO | 676.8K | — | 1.22M | 3.70M | 304.6K | 19.0K | 5.92M | 83.09% | ↗ |
| 14 | 2023 | Stephen Pakola, M.D. EVP, Chief Medical Officer | 498.2K | — | 2.02M | 616.4K | 156.9K | 19.0K | 3.31M | 79.61% | ↗ |
| 15 | 2023 | Olivier Danos, Ph.D. EVP, Chief Scientific Officer | 502.3K | — | 1.47M | 739.6K | 158.2K | 118.4K | 2.99M | 73.91% | ↗ |
| 16 | 2023 | Curran Simpson EVP, Chief Operating Officer | 512.9K | — | 1.51M | 739.6K | 166.7K | 19.0K | 2.95M | 76.32% | ↗ |
| 17 | 2023 | Curran Simpson President and CEO | 512.9K | — | 1.51M | 739.6K | 166.7K | 19.0K | 2.95M | 76.32% | ↗ |
| 18 | 2023 | Vit Vasista Former EVP, Chief Financial Officer | 500.0K | — | 1.03M | 924.5K | 147.5K | 19.0K | 2.62M | 74.55% | ↗ |
| 19 | 2023 | Vit Vasista EVP, Chief Financial Officer | 500.0K | — | 1.03M | 924.5K | 147.5K | 19.0K | 2.62M | 74.55% | ↗ |
| 20 | 2022 | Kenneth T. Mills Former President and CEO | 650.8K | — | 1.23M | 3.51M | 351.4K | 17.5K | 5.75M | 82.28% | ↗ |
| 21 | 2022 | Kenneth T. Mills President and CEO | 650.8K | — | 1.23M | 3.51M | 351.4K | 17.5K | 5.75M | 82.28% | ↗ |
| 22 | 2022 | Olivier Danos, Ph.D. EVP, Chief Scientific Officer | 482.9K | — | 367.1K | 1.05M | 178.7K | 66.4K | 2.15M | 66.10% | ↗ |
| 23 | 2022 | Curran Simpson EVP, Chief Operating Officer | 474.9K | — | 367.1K | 1.05M | 185.2K | 17.5K | 2.10M | 67.69% | ↗ |
| 24 | 2022 | Curran Simpson President and CEO | 474.9K | — | 367.1K | 1.05M | 185.2K | 17.5K | 2.10M | 67.69% | ↗ |
| 25 | 2022 | Stephen Pakola, M.D. EVP, Chief Medical Officer | 479.0K | — | 305.4K | 875.5K | 177.2K | 17.5K | 1.85M | 63.67% | ↗ |
| 26 | 2022 | Vit Vasista Former EVP, Chief Financial Officer | 480.8K | — | 305.4K | 875.5K | 173.1K | 17.5K | 1.85M | 63.75% | ↗ |
| 27 | 2022 | Vit Vasista EVP, Chief Financial Officer | 480.8K | — | 305.4K | 875.5K | 173.1K | 17.5K | 1.85M | 63.75% | ↗ |
| 28 | 2021 | Kenneth T. Mills President and CEO | 631.8K | 600.0K | 1.84M | 5.06M | 473.9K | 16.7K | 8.62M | 80.03% | ↗ |
| 29 | 2021 | Patrick J. Christmas EVP, Chief Legal Officer | 439.0K | 425.0K | 620.6K | 1.71M | 230.5K | 16.7K | 3.44M | 67.69% | ↗ |
| 30 | 2021 | Vit Vasista EVP, Chief Financial Officer | 466.8K | 525.0K | 557.6K | 1.54M | 245.1K | 16.7K | 3.35M | 62.54% | ↗ |
| 31 | 2021 | Curran Simpson EVP, Chief Operating Officer | 448.1K | 225.0K | 620.6K | 1.70M | 235.2K | 16.7K | 3.25M | 71.52% | ↗ |
| 32 | 2021 | Curran Simpson EVP, Chief Operations and Technology Officer | 448.1K | 225.0K | 620.6K | 1.70M | 235.2K | 16.7K | 3.25M | 71.52% | ↗ |
| 33 | 2021 | Olivier Danos, Ph.D. EVP, Chief Scientific Officer | 455.6K | 100.0K | 521.7K | 1.43M | 239.2K | 47.3K | 2.80M | 69.90% | ↗ |
| 34 | 2020 | Kenneth T. Mills President and CEO | 613.4K | — | — | 6.65M | 368.0K | 16.4K | 7.64M | 86.95% | ↗ |
| 35 | 2020 | Vit Vasista EVP, Chief Financial Officer | 453.2K | — | — | 1.23M | 181.3K | 16.4K | 1.88M | 65.41% | ↗ |
| 36 | 2020 | Vit Vasista Senior Vice President, Chief Financial Officer | 453.2K | — | — | 1.23M | 181.3K | 16.4K | 1.88M | 65.41% | ↗ |
| 37 | 2020 | Patrick J. Christmas Senior Vice President, Chief Legal Officer | 426.3K | — | — | 1.23M | 170.5K | 16.4K | 1.84M | 66.75% | ↗ |
| 38 | 2020 | Patrick J. Christmas EVP, Chief Legal Officer | 426.3K | — | — | 1.23M | 170.5K | 16.4K | 1.84M | 66.75% | ↗ |
| 39 | 2020 | Olivier Danos, Ph.D. EVP, Chief Scientific Officer | 433.9K | — | — | 1.18M | 173.6K | 16.4K | 1.81M | 65.45% | ↗ |
| 40 | 2020 | Olivier Danos, Ph.D. Senior Vice President, Chief Scientific Officer | 433.9K | — | — | 1.18M | 173.6K | 16.4K | 1.81M | 65.45% | ↗ |
| 41 | 2020 | Curran Simpson EVP, Chief Operations and Technology Officer | 428.2K | — | — | 1.13M | 174.0K | 16.4K | 1.75M | 64.67% | ↗ |
| 42 | 2020 | Curran Simpson Senior Vice President, Chief Operations and Technology Officer | 428.2K | — | — | 1.13M | 174.0K | 16.4K | 1.75M | 64.67% | ↗ |
| 43 | 2020 | Curran Simpson EVP, Chief Operating Officer | 428.2K | — | — | 1.13M | 174.0K | 16.4K | 1.75M | 64.67% | ↗ |
| 44 | 2019 | Kenneth T. Mills President and CEO | 595.5K | — | — | 5.16M | 375.2K | 16.1K | 6.15M | 83.95% | ↗ |
| 45 | 2019 | Steve Pakola, M.D. Senior Vice President, Chief Medical Officer | 305.3K | — | — | 3.46M | 126.7K | 16.1K | 3.91M | 88.54% | ↗ |
| 46 | 2019 | Vit Vasista EVP, Chief Financial Officer | 440.0K | — | — | 1.55M | 180.4K | 16.1K | 2.18M | 70.87% | ↗ |
| 47 | 2019 | Vit Vasista Senior Vice President, Chief Financial Officer | 440.0K | — | — | 1.55M | 180.4K | 16.1K | 2.18M | 70.87% | ↗ |
| 48 | 2019 | Olivier Danos, Ph.D. Senior Vice President, Chief Scientific Officer | 421.3K | — | — | 1.30M | 185.4K | 16.1K | 1.93M | 67.67% | ↗ |
| 49 | 2019 | Olivier Danos, Ph.D. EVP, Chief Scientific Officer | 421.3K | — | — | 1.30M | 185.4K | 16.1K | 1.93M | 67.67% | ↗ |
| 50 | 2019 | Patrick J. Christmas Senior Vice President, Chief Legal Officer | 406.0K | — | — | 1.22M | 188.8K | 16.1K | 1.83M | 66.68% | ↗ |
| 51 | 2019 | Patrick J. Christmas EVP, Chief Legal Officer | 406.0K | — | — | 1.22M | 188.8K | 16.1K | 1.83M | 66.68% | ↗ |
| 52 | 2019 | Curran Simpson EVP, Chief Operations and Technology Officer | 382.4K | — | — | 1.25M | 177.8K | 16.1K | 1.83M | 68.43% | ↗ |
| 53 | 2019 | Curran Simpson Senior Vice President, Chief Operations and Technology Officer | 382.4K | — | — | 1.25M | 177.8K | 16.1K | 1.83M | 68.43% | ↗ |
| 54 | 2018 | Kenneth T. Mills President and CEO | 546.4K | — | — | 3.90M | 480.8K | 15.8K | 4.94M | 78.88% | ↗ |
| 55 | 2018 | Vit Vasista Senior Vice President, Chief Financial Officer | 379.3K | — | — | 1.31M | 239.0K | 15.8K | 1.94M | 67.39% | ↗ |
| 56 | 2018 | Vittal Vasista Chief Financial Officer | 379.3K | — | — | 1.31M | 239.0K | 15.8K | 1.94M | 67.39% | ↗ |
| 57 | 2018 | Curran Simpson Senior Vice President, Product Development and Chief Technology Officer | 371.3K | — | — | 1.31M | 204.7K | 14.8K | 1.90M | 68.92% | ↗ |
| 58 | 2018 | Curran Simpson Senior Vice President, Chief Operations and Technology Officer | 371.3K | — | — | 1.31M | 204.7K | 14.8K | 1.90M | 68.92% | ↗ |
| 59 | 2018 | Stephen Yoo, M.D. Former Chief Medical Officer | 397.9K | — | — | 1.31M | 160.0K | 15.8K | 1.88M | 69.55% | ↗ |
| 60 | 2018 | Olivier Danos, Ph.D. Chief Scientific Officer | 409.0K | — | — | 982.7K | 207.6K | 14.5K | 1.61M | 60.90% | ↗ |
| 61 | 2018 | Olivier Danos, Ph.D. Senior Vice President, Chief Scientific Officer | 409.0K | — | — | 982.7K | 207.6K | 14.5K | 1.61M | 60.90% | ↗ |
| 62 | 2017 | Kenneth T. Mills President and CEO | 530.5K | — | — | 1.73M | 278.5K | 15.5K | 2.56M | 67.78% | ↗ |
| 63 | 2017 | Kenneth T. Mills President and Chief Executive Officer | 530.5K | — | — | 1.73M | 278.5K | — | 2.54M | 68.19% | ↗ |
| 64 | 2017 | Olivier Danos, Ph.D. Chief Scientific Officer | 307.7K | 50.0K | — | 1.39M | 108.9K | 15.5K | 1.87M | 74.25% | ↗ |
| 65 | 2017 | Olivier Danos, Ph.D. Senior Vice President, Chief Scientific Officer | 307.7K | 50.0K | — | 1.39M | 108.9K | 15.5K | 1.87M | 74.25% | ↗ |
| 66 | 2017 | Vit Vasista Senior Vice President, Chief Financial Officer | 365.4K | — | — | 667.0K | 137.5K | 15.5K | 1.19M | 56.27% | ↗ |
| 67 | 2017 | Vittal Vasista Chief Financial Officer | 365.4K | — | — | 667.0K | 137.5K | 15.5K | 1.19M | 56.27% | ↗ |
| 68 | 2017 | Stephen Yoo, M.D. Former Chief Medical Officer | 386.3K | — | — | 533.6K | 141.9K | 15.5K | 1.08M | 49.53% | ↗ |
| 69 | 2017 | Curran Simpson Senior Vice President, Product Development and Chief Technology Officer | 360.5K | — | — | 400.2K | 137.2K | 14.4K | 912.3K | 43.87% | ↗ |
| 70 | 2016 | Kenneth T. Mills President and CEO | 514.9K | — | — | 1.98M | 206.0K | 17.7K | 2.72M | 72.83% | ↗ |
| 71 | 2016 | Kenneth T. Mills President and Chief Executive Officer | 514.9K | — | — | 1.98M | 206.0K | — | 2.70M | 73.30% | ↗ |
| 72 | 2016 | Faraz Ali Chief Business Officer | 262.3K | 60.0K | — | 1.71M | 75.2K | — | 2.11M | 81.16% | ↗ |
| 73 | 2016 | Curran Simpson Senior Vice President, Product Development and Chief Technology Officer | 349.9K | — | 825.6K | 88.0K | 107.2K | 11.2K | 1.38M | 66.11% | ↗ |
| 74 | 2016 | Curran Simpson Senior Vice President, Technical Operations | 349.9K | — | 825.6K | 88.0K | 107.2K | — | 1.37M | 66.65% | ↗ |
| 75 | 2016 | Vittal Vasista Chief Financial Officer | 349.9K | — | — | 659.8K | 104.1K | 16.2K | 1.13M | 58.39% | ↗ |
| 76 | 2016 | Stephen Yoo, M.D. Former Chief Medical Officer | 374.9K | — | — | 615.8K | 103.4K | 17.5K | 1.11M | 55.40% | ↗ |
| 77 | 2015 | Kenneth T. Mills President and Chief Executive Officer | 500.0K | 275.0K | — | 615.9K | — | — | 1.39M | 44.28% | ↗ |
| 78 | 2015 | Stephen Yoo, M.D. Chief Medical Officer | 340.0K | 130.9K | — | 156.8K | — | — | 627.7K | 24.98% | ↗ |
| 79 | 2015 | Vittal K. Vasista Chief Financial Officer | 315.0K | 121.3K | — | 67.2K | — | — | 503.5K | 13.34% | ↗ |
| 80 | 2014 | Kenneth T. Mills President and Chief Executive Officer | 500.0K | 250.0K | — | 361.2K | — | — | 1.15M | 31.49% | ↗ |
| 81 | 2014 | Vittal K. Vasista Chief Financial Officer | 300.0K | 120.0K | — | 216.7K | — | — | 665.9K | 32.54% | ↗ |
| 82 | 2014 | Stephen Yoo, M.D. Chief Medical Officer | 65.6K | 20.0K | — | 121.5K | — | — | 211.4K | 57.46% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Curran Simpson | President, Chief Executive Officer & Director | 1M | male |
| Patrick J. Christmas | Executive Vice President & Chief Strategy and Legal Officer | 944.7K | male |
| Stephen Pakola | Executive Vice President & Chief Medical Officer | 785.0K | — |
| Olivier Danos | Executive Vice President & Chief Scientific Officer | 770.1K | — |
| Mitchell Chan | Executive Vice President & Chief Financial Officer | 205.3K | male |
| Craig Malzahn | Executive Vice President of Product Development & Chief Technology Officer | — | male |
| Nina Hunter | SVP of Global Regulatory Strategy and Quality | — | female |
| Sarah Thomas | Senior Vice President of Quality | — | female |
| Shiva G. Fritsch | Chief Communications & People Officer | — | female |
| Jahannaz Dastgir | Clinical Development Lead | — | — |
| Ram Palanki | Executive Vice President & Chief Commercial Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RGNX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
